Author

A. V. van Muyden

h-index 4 View on Semantic Scholar

We have 2 of 14 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

of T cells engineered to express a defined γδTCR

J. Kuball, J. M. dos Santos, T. Straetemans et al. · 0 citations

Clinical trial Sep 2026

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.

This phase 1 dose-escalation part of the ATALANTA-1 phase 1/2, single-arm study was executed in five hospitals in the Netherlands and Belgium to evaluate the safety and determine the recommended phase 2 dose of GLPG5101.

M. Kersten, M. Kuipers, P. Mutsaers et al. · The Lancet Haematology · 0 citations